1,000,000 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Bought by Boxer Capital Management LLC

Boxer Capital Management LLC purchased a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,000,000 shares of the company's stock, valued at approximately $9,950,000. Boxer Capital Management LLC owned 1.90% of Kodiak Sciences as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KOD. Barclays PLC boosted its position in shares of Kodiak Sciences by 65.5% during the 3rd quarter. Barclays PLC now owns 79,658 shares of the company's stock valued at $208,000 after purchasing an additional 31,527 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Kodiak Sciences by 220.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock valued at $117,000 after buying an additional 30,735 shares during the last quarter. State Street Corp boosted its position in Kodiak Sciences by 1.8% in the third quarter. State Street Corp now owns 816,634 shares of the company's stock worth $2,131,000 after purchasing an additional 14,711 shares during the last quarter. Peapod Lane Capital LLC purchased a new position in Kodiak Sciences in the fourth quarter valued at about $1,660,000. Finally, Geode Capital Management LLC raised its position in shares of Kodiak Sciences by 1.7% in the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company's stock valued at $2,007,000 after purchasing an additional 12,783 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 target price on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Stock Up 1.3 %

Kodiak Sciences stock traded up $0.05 during midday trading on Wednesday, reaching $3.85. The stock had a trading volume of 129,056 shares, compared to its average volume of 346,371. The firm has a market cap of $203.10 million, a price-to-earnings ratio of -1.05 and a beta of 2.42. Kodiak Sciences Inc. has a 52-week low of $1.92 and a 52-week high of $11.60. The company has a fifty day moving average of $3.28 and a 200 day moving average of $5.49.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.06. Equities research analysts predict that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.